The Role of Mesenchymal Stem Cell and Exosome in Treating Pilonidal Sinus Disease in Children

Launched by MUSTAFA AZIZOĞLU · Apr 26, 2024

Keywords

ClinConnect Summary

This clinical trial is studying a new treatment for children with a condition called pilonidal sinus disease, which involves painful and persistent wounds that don't heal well. The researchers want to see if using special cells called mesenchymal stem cells (MSCs) and their secretions, known as exosomes, can help these wounds heal better than the usual treatment. Children aged 0 to 18 who have chronic non-healing wounds or pilonidal sinus disease may be eligible to participate. Those who have certain health issues, like epilepsy, diabetes, or hypertension, will not be included in the trial.

If a child is selected for the study, they will be placed in one of two groups. One group will receive the standard treatment, while the other group will receive the new treatment made from the stem cells. The goal is to find out how effective and safe this new treatment is. Participation in the trial may provide access to this innovative therapy, which could potentially lead to better healing outcomes for children struggling with these difficult wounds.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 0-18 years children.
• • Patients with chronic non-healing wound and pilonidal sinus diseases.
• Exclusion Criteria:
• • Patients with epilepsia
• • Patients with diabetes
• • Patients with hypertension
• • Patients with chronic other diseases.